NLS Pharmaceutics Ltd NLSP 深 滬
等待開盤 09-24 09:30:00 美东时间
0.762
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.762
- 總市值 373.99万
- 52周最高 41.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.40
- 委 比 0.00%
- 總股本 490.80万
- 歷史最高 2940.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 7.40
- 每 手 1
- 風險率 3.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NewcelX GAAP EPS of -$0.96
NewcelX press release (NCEL): 1H GAAP EPS of -$0.96. As of June 30, 2026, the company’s total equity was positive at $6,041, including cash and cash equivalents of $710. More on NLS Pharmaceutics Hist...
09-19 04:26
NLS Pharmaceutics GAAP EPS of -$2.16
NLS Pharmaceutics press release (NCEL): FY GAAP EPS of -$2.16. Financial Highlights for the Period Ended December 31, 2025Cash and cash equivalents as of December 31, 2025 were $2.2 million. Net loss ...
05-01 20:48
NewcelX prices $1.35M equity financing
NewcelX (NCEL) announced on Wednesday that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last clo...
04-01 20:10
NewCelX Appoints EY as New Auditor Following Merger
NewcelX ( ($NCEL) ) has issued an update. NewCelX Ltd., previously known as NLS...
2025-11-21 05:57
NewcelX CEO Issues Letter to Shareholders
ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative an...
2025-11-04 20:00
NewcelX Unveils Strategic Roadmap Post-Merger with NLS Pharmaceutics
NewcelX ( ($NCEL) ) has provided an announcement. On November 3, 2025, NewcelX ...
2025-11-03 22:20
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRN...
2025-10-31 04:15
NLS Pharma And Aexon Labs Expand DOXA Platform With AEX-6xx Series, New Generation Of Small Molecules Targeting Arousal Stability, Cognition, And Neuroprotection
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective ProgramsSupported by Solid Cash Position and Strategic Funding OutlookZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.
2025-10-30 19:15
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS ...
2025-10-30 19:00
